ReviewCancers2019
New Era for Next-Generation Sequencing in Japan.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.Cancer science · 2024Trial
- Tepotinib in Non-Small-Cell Lung Cancer withThe New England journal of medicine · 2020Trial
- Correlation between variant call accuracy and quality parameters in comprehensive cancer genomic profiling tests.Practical laboratory medicine · 2024Article
- Utility of needle biopsy in centrally located lung cancer for genome analysis: a retrospective cohort study.BMC pulmonary medicine · 2023Article
- Article
- Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area.Healthcare (Basel, Switzerland) · 2023Article
- PredictingTranslational cancer research · 2022Article
- Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA Consortium.Cancers · 2022Article
- A case report of primary signet ring cell carcinoma of the lung: imaging study and literature review.Translational lung cancer research · 2021Article
- Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.Japanese journal of clinical oncology · 2021Article
- Article
- Comparative study of the loop-mediated isothermal amplification method and the QIAGENJournal of thoracic disease · 2021Article
- Implementation of clinical sequencing for molecular profiling in patients with advanced cancer.Cancer biomarkers : section A of Disease markers · 2021Observational
- Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples.Thoracic cancer · 2021Article
- Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore.Asia-Pacific journal of clinical oncology · 2020Review
- Life Threatening haemoptysis in primary lung cancer-signet ring cell carcinoma.Respiratory medicine case reports · 2020Article
- Multidisciplinary therapy strategy of precision medicine in clinical practice.Clinical and translational medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.